Stockreport

Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data

GALENA BIOPHARMA  (GALE) 
PDF SAN RAMON, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics [Read more]